《即日市評》港股反覆上落 成交不足千億 科網及車股弱
港股聖誕假期後,今日反覆上落。市場消除對Omicron新冠變種導致美航班取消影響經濟的疑慮,美股道指及納指各升1%及1.4%;執筆之時美國十年期國債孳息率升至1.474釐,美匯指數跌至96.08,美股道指期貨最新升44點或0.12%,納指期貨最新升0.22%。內地昨新增本土確診病例182例,其中西安佔175例;人行開展2,000億人民幣7天期逆回購操作,單日淨投放1,900億人民幣。上證綜指全日升14點或0.39%收3,630點、深證成指升0.8%,內地創業板指數升1.1%,滬深兩市成交額共1萬億人民幣。
恆指高開58點,早段曾升95點一度高見23,319點,其後曾倒跌124點一度低見23,099點,最終全日升56點或0.24%,收23,280點;國指跌7點或0.09%,收8,194點;恆生科技指數跌49點或0.89%,收5,569點。大市全日成交總額997.41億元,滬港通南下交易淨流入6.58億元人民幣,深港通南下交易淨流出4.67億元人民幣。
中國恆大(03333.HK)全日股價彈9.5%收1.62元,恆大物業(06666.HK)揚2.3%。恆大主席許家印指截至12月26日恆大全國項目復工率爲91.7%及確保12月交樓3.9萬套。人行行長易綱接受《新華社》訪問指,個別房企出險後,有關部門和地方政府已積極採取措施,穩妥有序化解風險。
【科網股造淡 汽車股走弱】
科網股普遍造淡,騰訊(00700.HK)股價走低2.1%,美團(03690.HK)及快手(01024.HK)股價各下滑1.2%及4%。瑞銀指,快手與美團近日宣佈達成戰略合作,美團將在快手開放平臺推出美團小程序,美團商家將可展示商品、線上交易與售後服務。瑞銀指,短視頻及電商直播仍將是未來主流,快手用戶瀏覽時間份額高於公司於線上廣告和電商市場的佔有率,預期快手將通過與美團的合作加快變現,並對抗兩者的共同競爭對手字節跳動,惟現階段難以量化合作所帶來的效用。
中資汽車股造淡,吉利(00175.HK)、長汽(02333.HK)及北汽(01958.HK)股價各走低3.9%、2%及4.4%。發改委及商務部昨日(27日)發佈《外商投資準入特別管理措施(負面清單)(2021年版)》和《自由貿易試驗區外商投資準入特別管理措施(負面清單)(2021年版)》,自明年1月1日起施行,當中提到汽車製造領域取消乘用車製造外資股比限制,以及同一家外商可在國內建立兩家及兩家以下生產同類整車產品的合資企業的限制。
【沽空率上升 開拓藥業瀉】
港股今日市寬變動不大,主板股票的升跌比率爲22比21(上日爲20比16);恆指成份股今日50只股份上升,下跌股份13只,升跌比率爲78比20(上日爲50比36)。大市今日錄沽空127.74億元,佔可沽空股份成交821.31億元的15.554%(上日13.717%)。
開拓藥業-B(09939.HK)全日股價急瀉70.4%收13.4元。開拓藥業-B公佈其普克魯胺治療新冠非住院患者臨牀試驗,未達到統計學顯着性。開拓藥業創始人、董事長兼首席執行官童友之在電話會上表示,結果非常明顯顯示,該藥商業計劃延遲,對公司造成很大的一個問題。
據海通國際12月初曾發表報告,當時指開拓藥業旗下普克魯胺治療新冠藥前期數據理想,若臨牀數據與前期保持一致,當時料普克魯胺於2022年新冠適應症有望在全球帶來營253.2億人民幣(未經風險調整),該行時料開拓藥業淨利潤可從2021年淨虧損2,600萬人民幣,至2022年扭虧爲盈達84.84億人民幣,此基於普克魯胺因素。但公司最新公告指普克魯胺治療新冠非住院患者臨牀試驗未達到統計學顯着性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.